Asundexian does not reduce the risk of recurrent strokes after non-cardioembolic ischemic stroke
1. The composite of MRI-detected brain infarcts and symptomatic ischemic stroke was comparable across different doses of asundexian and placebo. ...
Tag: direct oral anticoagulant (DOAC)
Left atrial appendage occlusion is an effective alternative to oral anticoagulation in atrial fibrillation
1. The overall benefit of left atrial appendage occlusion (LAOO) for prevention of stroke in patients with atrial fibrillation (AF) ...
#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage
Click to read this study in JAMA Network Open.
Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation
1. Asundexian 50 mg resulted in a lower rate of bleeding compared to apixaban 5 mg twice daily. 2. The ...
Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19
1. The primary efficacy outcome of symptomatic and asymptomatic venous thromboembolism was significantly lower in the rivaroxaban group (3.14%) compared ...
Rivaroxaban superior to aspirin at reducing recurrent stroke in patients with embolic stroke of undetermined source and left ventricular dysfunction: (NAVIGATE ESUS Trial)
1. Rivaroxaban was superior to aspirin in reducing recurrent stroke or systemic embolism among patients with recent embolic stroke of ...
Aspirin treatment without indication in patients on direct oral anticoagulants may increase the risk of bleeding events
1. In patients treated with direct oral anticoagulants (DOACs) for atrial fibrillation or venous thromboembolism (VTE), adding aspirin (ASA) was ...
Direct oral anticoagulants more effective in patients with valvular atrial fibrillation
1. Patients who received a direct oral anticoagulant had a lower risk of thromboembolic events and major bleeds compared to ...
Low dose edoxaban prevents stroke in elderly patients with atrial fibrillation
1. Low dose edoxaban was superior to placebo in preventing stroke or systemic embolism for very elderly patients with nonvalvular ...